Related Experiment Video
Updated: Aug 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Rationalizing the heart failure trials: from theory to practice
1Department of Clinical Pharmacology, Ninewells Hospital, Dundee, UK.
Abstract:
It is 10 years since the CONSENSUS I study showed that ACE inhibitors improved mortality in heart failure. This finding has been confirmed in numerous trials, for example SOLVD, SAVE. Indeed, in the intervening 10 years, many other potential therapies have been examined in mortality trials, but so far no other therapy has had as good effect on mortality as ACE inhibitors. The other therapies which have been examined are digoxin, amlodipine, beta-blockers, amiodarone, etc. Despite ACE inhibitors being a very effective therapy for heart failure, there is still remarkable under-use of them in clinical practice. The reason for this needs to be explained further, but fear of hypothermia and renal dysfunction appear to be major factors.
Insights
Angiotensin-converting enzyme (ACE) inhibitors remain the most effective treatment for improving mortality in heart failure patients. Despite proven benefits, their clinical use is limited by concerns about side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The CONSENSUS I study, 10 years ago, established Angiotensin-converting enzyme (ACE) inhibitors as beneficial for heart failure mortality.
- Subsequent trials like SOLVD and SAVE have confirmed these findings, highlighting ACE inhibitors' consistent efficacy.
Purpose of the Study:
- To review the established efficacy of ACE inhibitors in heart failure mortality.
- To investigate the persistent underutilization of ACE inhibitors in clinical practice despite their proven benefits.
Main Methods:
- Review of landmark clinical trials (e.g., CONSENSUS I, SOLVD, SAVE) evaluating heart failure therapies.
- Analysis of potential reasons for the under-use of ACE inhibitors in current medical practice.
Main Results:
- ACE inhibitors demonstrate superior mortality benefits in heart failure compared to other examined therapies, including digoxin, amlodipine, beta-blockers, and amiodarone.
- Despite strong evidence, ACE inhibitors are underused in heart failure management.
Conclusions:
- ACE inhibitors are a cornerstone therapy for improving heart failure outcomes.
- Addressing clinical inertia and patient/physician concerns regarding side effects like hypothermia and renal dysfunction is crucial for increasing ACE inhibitor adoption.
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions

